Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Frequency of use of immunosuppressive agents during the study

From: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

Immunosuppressive drugs Placebo (n = 13) Belimumab
   1.0 mg/kg (n = 15) 4.0 mg/kg (n = 14) 10 mg/kg (n = 14) 20 mg/kg (n = 14) All active (n = 57)
Prednisone 9 (69) 14 (93) 9 (54) 10 (71) 8 (57) 41 (72)
Methotrexate 2 (15) 1 (7) 0 2 (14) 3 (21) 6 (11)
Azathioprine 5 (38) 2 (13) 2 (13) 2 (14) 1 (7) 7 (12)
Mycophenolate 0 1 (7) 1 (7) 1 (7) 5 (36) 8 (14)
None 3 (23) 1 (7) 5 (36) 3 (21) 3 (21) 12 (21)